Quarterly report pursuant to Section 13 or 15(d)

Acquisitions (Details Textual)

v3.5.0.2
Acquisitions (Details Textual) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Mar. 07, 2016
Stock Issued During Period, Value, New Issues     $ 668,437    
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total $ (3,823,281) $ (1,541,353) (6,265,714) $ (4,342,439)  
Jade Therapeutics, Inc [Member]          
Business Acquisition, Percentage of Voting Interests Acquired         100.00%
Business Combination, Consideration Transferred, Liabilities Incurred     $ 300,000    
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares     765,728    
Percentage Of Common Stock Issued     90.00%    
Percentage Of Common Stock To Be Issued     10.00%    
Business Combination, Contingent Consideration, Liability $ 2,164,451   $ 2,164,451    
Stock Issued During Period, Value, New Issues     $ 2,910,000    
Business Acquisition, Share Price $ 3.80   $ 3.80    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents $ 186,000   $ 186,000    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets 369,000   369,000    
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total     $ 118,000    
Finite-Lived Intangible Asset, Useful Life     3 years    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables $ 46,000   $ 46,000    
Jade Therapeutics, Inc [Member] | Selling, General and Administrative Expenses [Member]          
Business Combination, Acquisition Related Costs     $ 234,000